Michael joined the firm’s investment team in 2021, with a focus on our biotech portfolio of companies.
Prior to joining Santé, Michael was a postdoctoral fellow at MIT’s Computer Science and Artificial Intelligence Laboratory and a visiting fellow at Harvard’s Department of Stem Cell and Regenerative Biology. His research merged deep learning and adult stem cell models to dissect the mechanisms driving brain disorders.
Michael earned his PhD from Cold Spring Harbor Laboratory in Biological Sciences and his BS from the University of Illinois at Urbana-Champaign in Molecular & Cellular Biology and English.
What, in your opinion, is one of the greatest innovations of the 21st Century?
The gene-editing technology CRISPR has revolutionized our ability to understand biology and treat disease. It is by far the most consequential innovation of this century.
What great advice have you received?
Never stop learning.